{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:12:15Z","timestamp":1762254735582,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111296","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T21:29:02Z","timestamp":1701638942000},"page":"111296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The effects of the LaSota strain of oncolytic Newcastle disease virus vaccine on cervical intraepithelial neoplasia Patients-Clinical cohort study"],"prefix":"10.1016","volume":"126","author":[{"given":"Neda","family":"Sharifi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1260-2267","authenticated-orcid":false,"given":"Majid","family":"Bouzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mehdi Ranjbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10167","key":"10.1016\/j.intimp.2023.111296_b0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.intimp.2023.111296_b0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","article-title":"Cervical cancer: Epidemiology, risk factors and screening","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin J Cancer Res."},{"issue":"32","key":"10.1016\/j.intimp.2023.111296_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0968-8080(08)32399-4","article-title":"Cervical cancer: the route from signs and symptoms to treatment in South Africa","volume":"16","author":"van Schalkwyk","year":"2008","journal-title":"Reprod. Health Matters."},{"key":"10.1016\/j.intimp.2023.111296_b0020","unstructured":"V. Mello, R.K. Sundstrom, Cervical intraepithelial neoplasia, StatPearls [Internet], StatPearls Publishing. (2021).Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544371\/."},{"key":"#cr-split#-10.1016\/j.intimp.2023.111296_b0025.1","unstructured":"J.D. Wright B. Goff A. Chakrabarti Cervical intraepithelial neoplasia: Management UptoDate [Internet] UptoDate [Internet][updated 2020 October 7"},{"key":"#cr-split#-10.1016\/j.intimp.2023.111296_b0025.2","unstructured":"cited 2020 December 7]. Available from: https:\/\/www. uptod ate. com\/conte nts\/cervi cal-intra epith elial-neopl asia-manag ement (2022)."},{"issue":"5","key":"10.1016\/j.intimp.2023.111296_b0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bpobgyn.2011.04.007","article-title":"Management options for cervical intraepithelial neoplasia","volume":"25","author":"Petry","year":"2011","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0035","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1038\/s41598-020-80176-6","article-title":"Changes to the cervicovaginal microbiota and cervical cytokine profile following surgery for cervical intraepithelial neoplasia","volume":"11","author":"Kawahara","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.111296_b0040","doi-asserted-by":"crossref","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2023.111296_b0045","doi-asserted-by":"crossref","unstructured":"B. Burman G. Pesci D. Zamarin Newcastle disease virus at the forefront of cancer immunotherapy 2020 Cancers12(12), p.3552.","DOI":"10.3390\/cancers12123552"},{"issue":"6","key":"10.1016\/j.intimp.2023.111296_b0050","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2023.111296_b0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13337-020-00612-z","article-title":"Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death","volume":"31","author":"Al-Ziaydi","year":"2020","journal-title":"VirusDisease"},{"issue":"3","key":"10.1016\/j.intimp.2023.111296_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003950","article-title":"Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3\u03b1 Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2023.111296_b0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: Current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sjbs.2019.04.015","article-title":"Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis","volume":"27","author":"Keshavarz","year":"2020","journal-title":"Saudi J. Biological Sci."},{"key":"10.1016\/j.intimp.2023.111296_b0075","doi-asserted-by":"crossref","first-page":"104438","DOI":"10.1016\/j.micpath.2020.104438","article-title":"Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways","volume":"147","author":"Mozaffari Nejad","year":"2020","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0080","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/vco.12915","article-title":"Newcastle disease virus LaSota strain induces apoptosis and activates the TNF\u03b1\/NF-\u03baB pathway in canine mammary carcinoma cells","volume":"27","author":"Wang","year":"2023","journal-title":"Vet. Comp. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0085","doi-asserted-by":"crossref","first-page":"040006","DOI":"10.1063\/5.0094322","article-title":"The anti-cancer effect of LaSota strain of newcastle Disease Virus (NDV) against Iraqi breast cancer cell line AMJ13","volume":"2398","author":"Ghali","year":"2022","journal-title":"AIP Conf. Proc."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0090","first-page":"45","article-title":"Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity","volume":"13","author":"Walter","year":"2012","journal-title":"Jop"},{"key":"10.1016\/j.intimp.2023.111296_b0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.24996\/ijs.2020.61.2.5","article-title":"In vitro oncolytic activity of non-virulent Newcastle disease virus LaSota strain against mouse mammary adenocarcinoma","author":"Hassan","year":"2020","journal-title":"Iraqi J. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2023.111296_b0100","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00705-011-0987-y","article-title":"Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by newcastle disease virus","volume":"156","author":"Bian","year":"2011","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1743-422X-8-385","article-title":"The matrix (M) protein of newcastle disease virus binds to human bax through its BH3 domain","volume":"8","author":"Molouki","year":"2011","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mc15f02s01","article-title":"Newcastle disease virus: Propagation, quantification, and Storage","volume":"1","author":"McGinnes","year":"2006","journal-title":"Curr. Protoc. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111296_b0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111296_b0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-0934(88)90132-2","article-title":"Titration of avirulent Newcastle disease virus by the plaque assay method","volume":"20","author":"Kournikakis","year":"1988","journal-title":"J. Virological Methods."},{"issue":"3","key":"10.1016\/j.intimp.2023.111296_b0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","article-title":"An optimized clinical regimen for the oncolytic virus PV701","volume":"13","author":"Hotte","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2023.111296_b0130","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","article-title":"A Phase 1 Clinical Study of Intravenous Administration of PV701, an oncolytic virus, using two-step desensitization","volume":"12","author":"Laurie","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.111296_b0135","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2307\/1588867","article-title":"Reactions of human sera to avian adenoviruses and newcastle disease virus","author":"Miller","year":"1971","journal-title":"Avian Dis."},{"key":"10.1016\/j.intimp.2023.111296_b0140","first-page":"303","article-title":"Newcastle disease virus antibodies in human sera","volume":"73","author":"Charan","year":"1981","journal-title":"Indian J. Med. Res."},{"issue":"10","key":"10.1016\/j.intimp.2023.111296_b0145","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.7314\/APJCP.2015.16.10.4271","article-title":"Expression of vimentin and Ki-67 proteins in cervical squamous cell carcinoma and their relationships with clinicopathological features","volume":"16","author":"Yu","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"issue":"2","key":"10.1016\/j.intimp.2023.111296_b0150","first-page":"1351","article-title":"Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions","volume":"18","author":"Shi","year":"2019","journal-title":"Oncol Lett."},{"issue":"2","key":"10.1016\/j.intimp.2023.111296_b0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0974-2727.199630","article-title":"Role of p16\/INK4a and Ki-67 as specific biomarkers for cervical intraepithelial neoplasia: An institutional study","volume":"9","author":"Hebbar","year":"2017","journal-title":"J Lab Physicians."},{"issue":"5","key":"10.1016\/j.intimp.2023.111296_b0160","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s10439-011-0498-8","article-title":"Automated detection of dual p16\/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical cancer risk stratification","volume":"40","author":"Gertych","year":"2012","journal-title":"Ann Biomed Eng."},{"issue":"4","key":"10.1016\/j.intimp.2023.111296_b0165","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.31557\/APJCP.2021.22.4.1225","article-title":"Comparison of cervical levels of interleukins-6 and -8 in patients with and without cervical intraepithelial neoplasia","volume":"22","author":"Vahedpour","year":"2021","journal-title":"Asian Pac J Cancer Prev."},{"issue":"3","key":"10.1016\/j.intimp.2023.111296_b0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.RVI.0000058422.01661.1E","article-title":"Becker young investigator award: Intraarterial adenovirus for metastatic gastrointestinal cancer: Activity, radiographic response, and survival","volume":"14","author":"Sze","year":"2003","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"10","key":"10.1016\/j.intimp.2023.111296_b0175","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ni.2406","article-title":"From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines","volume":"13","author":"Banchereau","year":"2012","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000445161","article-title":"Cytokines of cervical mucosa and human papilloma virus infection of the cervix: A descriptive study","volume":"60","author":"Daniilidis","year":"2016","journal-title":"Acta Cytologica."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0090-8258(90)90316-D","article-title":"Interferon \u03b3 treatment for cervical intraepithelial neoplasia","volume":"37","author":"Iwasaka","year":"1990","journal-title":"Gynecologic Oncology."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0190","first-page":"85","article-title":"Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis","volume":"21","author":"Washburn","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12985-020-01326-w","article-title":"Oncolytic newcastle disease virus delivered by mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment","volume":"17","author":"Keshavarz","year":"2020","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.intimp.2023.111296_b0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/mt.2015.172","article-title":"Activation of cyclic adenosine monophosphate pathway increases the sensitivity of cancer cells to the oncolytic virus M1","volume":"24","author":"Li","year":"2016","journal-title":"Mol Ther."},{"key":"10.1016\/j.intimp.2023.111296_b0205","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/mto.2015.11","article-title":"Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency","volume":"2","author":"Matveeva","year":"2015","journal-title":"Mol Ther Oncolytics."},{"issue":"12","key":"10.1016\/j.intimp.2023.111296_b0210","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41434-020-0145-9","article-title":"Optimization of oncolytic effect of newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses","volume":"28","author":"Liu","year":"2021","journal-title":"Gene Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:06:32Z","timestamp":1761588392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923016235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":43,"alternative-id":["S1567576923016235"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111296","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of the LaSota strain of oncolytic Newcastle disease virus vaccine on cervical intraepithelial neoplasia Patients-Clinical cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111296"}}